Role for Afatinib in p16-Negative Head and Neck Cancer?

This video reviews results of LUX-Head& Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.

Source: CancerNetwork - June 11, 2017 Category: Cancer & Oncology Authors: Barbara Burtness, MD Tags: Conferences/ASCO Street Team Head & Neck Cancer News Source Type: news